Publications by authors named "Duruta Weber"
Purpose: Clinical relapse is the major threat for patients with myelodysplastic syndrome (MDS) undergoing hematopoietic stem-cell transplantation (HSCT). Early detection of measurable residual disease (MRD) would enable preemptive treatment and potentially reduced relapse risk.
Methods: Patients with MDS planned for HSCT were enrolled in a prospective, observational study evaluating the association between MRD and clinical outcome.
Article Synopsis
- Gemtuzumab ozogamicin (GO) improves outcomes for older patients with acute myeloid leukemia (AML) when added to chemotherapy, but the effectiveness of a fractionated schedule compared to a single dose is uncertain.
- In a study of 852 older adults with AML, those receiving GO on days 1 and 4 showed a higher rate of complete remission with measurable residual disease (MRD) below 0.1% compared to those receiving a single dose, though overall complete remission rates were similar.
- The five-year overall survival rates were slightly better for patients receiving the fractionated schedule, especially among those who underwent allogeneic transplantation, indicating that multiple doses might enhance benefits in certain genetic profiles.
Stringent complete remission (sCR) of acute myeloid leukemia is defined as normal hematopoiesis after therapy. Less sCR, including non-sCR, was introduced as insufficient blood platelet, neutrophil, or erythrocyte recovery. These latter characteristics were defined retrospectively as postremission transfusion dependency and were suggested to be of prognostic value.
View Article and Find Full Text PDF